Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 27-35

  Karovic, S ^a   Wen, Y ^a   Karrison, T G ^a   Bakris, G L ^a   Levine, M R ^a   House, L K ^a   Wu, K ^a   Thomeas, V ^a   Rudek, M A ^b   Wright, J J ^c   Cohen, E E W ^a   Fleming, G F ^a   Ratain, M J ^a   Maitland, M L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELEVATED BLOOD PRESSURE; EVENING DOSAGE; FEMALE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; STEADY STATE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; YOUNG ADULT;

EID: 84902783979     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.63     Document Type: Article

References (37)

1. Fishman, M.N., Carducci, M., Bair, A.H., Chen, Y. & Rini, B.I. Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma patients. Annual Congress of the European Society for Medical Oncology (ESMO), Milan, Italy, 8-12 October 2010.
2. Keizer, R.J. et al. A model of hypertension and proteinuria in cancer patients treated with the anti-Angiogenic drug E7080. J. Pharmacokinet. Pharmacodyn. 37, 347-363 (2010)
3. Lindauer, A. et al. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin. Pharmacol. Ther. 87, 601-608 (2010)
4. Maitland, M.L. et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 15, 6250-6257 (2009)
5. Veronese, M.L. et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24, 1363-1369 (2006)
6. Mourad, J.J., des Guetz, G., Debbabi, H. & Levy, B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 19, 927-934 (2008)
7. Steeghs, N. et al. VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. J Clin Oncol (Meeting Abstracts) 24, 3037 (2006)
8. Dahlberg, S.E., Sandler, A.B., Brahmer, J.R., Schiller, J.H. & Johnson, D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol. 28, 949-954 (2010)
9. Rini, B.I. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103, 763-773 (2011)
10. Rini, B.I. et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin. Cancer Res. 17, 3841-3849 (2011)
11. Hurwitz, H.I. et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18, 273-280 (2013)
12. Maitland, M.L. More sound cancer therapy biomarker development with active noise control. Oncologist 18, 239-241 (2013)
13. Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005)
14. Jain, L. et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br. J. Clin. Pharmacol. 72, 294-305 (2011)
15. Houk, B.E., Bello, C.L., Poland, B., Rosen, L.S., Demetri, G.D. & Motzer, R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-Analysis. Cancer Chemother. Pharmacol. 66, 357-371 (2010)
16. Eechoute, K. et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin. Pharmacol. Ther. 92, 503-510 (2012)
17. Pickering, T.G., Shimbo, D. & Haas, D. Ambulatory blood-pressure monitoring. N. Engl. J. Med. 354, 2368-2374 (2006)
18. Jin, Y., Bies, R., Gastonguay, M.R., Stockbridge, N., Gobburu, J. & Madabushi, R. Misclassification and discordance of measured blood pressure from patients true blood pressure in current clinical practice: a clinical trial simulation case study. J. Pharmacokinet. Pharmacodyn. 39, 283-294 (2012)
19. Powers, B.J., Olsen, M.K., Smith, V.A., Woolson, R.F., Bosworth, H.B. & Oddone, E.Z. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann. Intern. Med. 154, 781-788, W (2011)
20. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. & Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999)
21. Papapetropoulos, A., Garcia-Cardena, G., Madri, J.A. & Sessa, W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139 (1997)
22. Facemire, C.S., Nixon, A.B., Griffiths, R., Hurwitz, H. & Coffman, T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54, 652-658 (2009)
23. Nakayama, M. et al. T-786->C mutation in the 5-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99, 2864-2870 (1999)
24. Nakayama, M. et al. A -786T>C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet. Genomics 16, 339-345 (2006)
25. Nishijima, T. et al. The endothelial nitric oxide synthase gene -786T/C polymorphism is a predictive factor for reattacks of coronary spasm. Pharmacogenet. Genomics 17, 581-587 (2007)
26. Rini, B.I. et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J. Clin. Pharmacol. 53, 491-504 (2013)
27. Lambrechts, D. et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13, 724-733 (2012)
28. Schneider, B.P. et al.; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26, 4672-4678 (2008)
29. Pickering, T.G. et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111, 697-716 (2005)
30. National Cancer Institute CTEP (2006) http://ctep.cancer.gov/ protocolDevelopment/electronic-Applications/docs/ctcaev3.pdf.
31. Li, L. et al. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-Tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878, 3033-3038 (2010)
32. Villarroel, M.C., Pratz, K.W., Xu, L., Wright, J.J., Smith, B.D. & Rudek, M.A. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest. New Drugs. 30, 2096-2102 (2012)
33. Zhao, M. et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 846, 1-7 (2007)
34. Boudou-Rouquette, P. et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 17, 1204-1212 (2012)
35. Hornecker, M. et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest. New Drugs 30, 1991-2000 (2012)
36. Tod, M. et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm. Res. 28, 3199-3207 (2011)
37. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007)